Whooping cough vaccine in pregnancy: new study looks at how antibodies pass to babies

NCT ID NCT05856396

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire Saint Pierre Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 200 women and their infants to understand how the whooping cough vaccine given during pregnancy affects the baby's immune protection. Researchers measured antibody levels in mothers and in umbilical cord blood at birth, as well as in infants after their own vaccines. The goal is to identify factors that influence how well protective antibodies are transferred from mother to child, which could improve vaccination strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pertussis-containing vaccines (Triaxis® and Vaxelis®)
What this could lead to: If successful, this could help design better vaccination schedules for pregnant women to protect newborns from whooping cough.
What could go wrong: This is an observational analysis of an already completed study, not a test of a new treatment. Results may not lead to immediate changes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULINS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections pertussis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULINS MATERNAL-FETAL RELATIONS PERTUSSIS VACCINATION; INFECTION

Contacts and locations

Locations

CHU Saint-Pierre

Brussels, 1000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.